The National Institute for Health and Care Excellence and the Medicines and Healthcare products Regulatory Agency have opened a new aligned pathway designed to bring medicines to NHS patients more quickly. From 1 April 2026, the two organisations are publishing licensing and value decisions at the same time, a move they say could shorten access timelines by three to six months.
The change is part of the UK government’s wider 10 Year Health Plan for England and Life Sciences Sector plan, which aims to get medicines to patients sooner while giving industry clearer development and submission routes. NICE said the new system is built around closer operational alignment, while preserving the independence and rigorous standards of both bodies. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started))
What the new route changes for companies and the NHS
Under the aligned pathway, decisions on licensing and value can be published in parallel, which NICE says should help companies plan development programmes earlier and reduce the risk of delays. The new Integrated Scientific Advice service also lets companies clarify evidence requirements from both organisations earlier in the process, using one meeting, one report and one payment. NICE says fees are around 25% lower than the previous service, and 40% lower for small and medium-sized enterprises. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started))
The process is intended to be more predictable for the NHS as well. Earlier notification of new medicines should support planning and adoption, while the new timetable is designed so topics can join the pathway without a separate application or additional fees once scheduling is confirmed. NICE says all topics submitted for scheduling from 1 October 2025 can follow the aligned pathway if notification is timely. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started))
Why the launch matters now
The launch comes as the UK continues to reshape its life sciences framework. NICE says the aligned pathway follows commitments made in the government’s health and life sciences plans, and the organisation has framed the change as a milestone for patients, the NHS and the pharmaceutical sector. It has also stressed that its appraisal standards are not changing, only the timing of decisions. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started))
NICE has recently also confirmed changes to its cost-effectiveness thresholds, with the updated approach set to take effect from April 2026. Together, the new threshold regime and the aligned pathway suggest a broader reset of how new medicines may be assessed and moved into routine NHS care. ([nice.org.uk](https://www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed?utm_source=openai))
Officials said the new system will be monitored continuously, including cases where same-time publication is not achieved, in order to refine the pathway over time. For drug developers, the message is clear: the UK is trying to make the route to NHS access faster, more coordinated and more transparent, while keeping the core evidence standards intact. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started))
Sursa foto: Imagine generată AI
